FDA Eases REMS Requirements During Coronavirus Outbreak

Sponsors who fail to meet certain Risk Evaluation and Mitigation Strategy (REMS) requirements won’t face FDA action during the COVID-19 outbreak, the agency announced.
Source: Drug Industry Daily